HC Wainwright Has Bullish Estimate for KPTI Q1 Earnings

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – HC Wainwright raised their Q1 2025 earnings per share estimates for Karyopharm Therapeutics in a report released on Thursday, February 20th. HC Wainwright analyst E. White now expects that the company will post earnings of ($0.29) per share for the quarter, up from their prior estimate of ($0.31). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.10) EPS, FY2026 earnings at ($0.87) EPS and FY2027 earnings at ($0.46) EPS.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Wednesday, February 19th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.02. The company had revenue of $30.54 million for the quarter, compared to analysts’ expectations of $30.29 million.

Other research analysts have also recently issued research reports about the company. Piper Sandler boosted their price target on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. Royal Bank of Canada restated an “outperform” rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. Finally, StockNews.com cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Karyopharm Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Karyopharm Therapeutics Trading Down 4.1 %

Shares of NASDAQ:KPTI opened at $0.57 on Monday. The stock has a fifty day simple moving average of $0.66 and a two-hundred day simple moving average of $0.75. The stock has a market capitalization of $72.07 million, a price-to-earnings ratio of -0.56 and a beta of 0.06. Karyopharm Therapeutics has a 12-month low of $0.51 and a 12-month high of $1.70.

Institutional Trading of Karyopharm Therapeutics

Large investors have recently modified their holdings of the company. Velan Capital Investment Management LP bought a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth $27,000. Focus Partners Wealth bought a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth $31,000. TD Waterhouse Canada Inc. bought a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth $32,000. Two Sigma Advisers LP grew its holdings in shares of Karyopharm Therapeutics by 145.5% in the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after acquiring an additional 45,400 shares during the period. Finally, Opti Capital Management LP bought a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth $85,000. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).